Table 4.
Relationship between the activation status of ALK, AKT and mTOR and the clinical features
|
ALK |
p-value |
p-AKT |
p-value |
p-mTOR |
p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| + (n = 62) | - (n = 41) | + (n = 54) | - (n = 17) | + (n = 57) | - (n = 14) | ||||
| Age (years) |
|
|
|
|
|
|
|
|
|
| Median |
17 |
48 |
|
28 |
29 |
|
25 |
40.5 |
|
| Range |
4–68 |
16–74 |
0.000* |
4–74 |
4–65 |
0.877 |
4–74 |
21–65 |
0.076 |
| Gender |
|
|
|
|
|
|
|
|
|
| Male |
40 |
27 |
|
41 |
14 |
|
44 |
11 |
|
| Female |
22 |
14 |
0.889 |
13 |
3 |
0.573 |
13 |
3 |
0.912 |
| Symptoms |
|
|
|
|
|
|
|
|
|
| A |
38 |
26 |
|
36 |
11 |
|
35 |
12 |
|
| B |
24 |
15 |
0.828 |
18 |
6 |
0.889 |
22 |
2 |
0.068 |
| Lesions |
|
|
|
|
|
|
|
|
|
| Nodal |
44 |
27 |
|
42 |
12 |
|
46 |
8 |
|
| Extranodal |
18 |
14 |
0.583 |
12 |
5 |
0.547 |
11 |
6 |
0.07 |
| Ann Arbor stage |
|
|
|
|
|
|
|
|
|
| I ~ II |
29 |
21 |
|
26 |
9 |
|
28 |
7 |
|
| III ~ IV | 33 | 20 | 0.659 | 28 | 8 | 0.730 | 29 | 7 | 0.953 |
*Statistically significant value.
Symptom B, systemic symptoms of fever, night sweats, and weight loss; Symptom A, absence of the systemic symptoms.